Please provide your email address to receive an email when new articles are posted on . The American Association for the Study of Liver Diseases Foundation has granted $3.42 million in research and ...

DURHAM, N.C., March 18, 2025 /PRNewswire/ -- The American Association for the Study of Liver Diseases (AASLD) is inviting members to apply as site principal investigators to participate in TARGET-LD, ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 16, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving ...

Please provide your email address to receive an email when new articles are posted on . AASLD warns that the 2025-2030 Dietary Guidelines for Americans remove clear, evidence-based alcohol consumption ...

At the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases (AASLD), a highlight came during the President's Choice Lecture, where former NIH director Francis ...

The American Association for the Study of Liver Diseases, along with other societies, has updated guidelines for the treatment of hepatitis C viral infection (HCV), including the use of direct-acting ...

WASHINGTON -- The annual Liver Meeting always draws a crowd, largely because there's pretty much something for everyone with an interest in hepatology. "We don't have a specific theme because we have ...

A late afternoon talk on the third day at The Liver Meeting 2014, evaluated the influence of some of the newer antiviral agents on "brain fog," a phenomenon quite commonly observed in hepatitis C ...

Editor's Note: Choosing Wisely®, an initiative of the American Board of Internal Medicine (ABIM) Foundation, comprises evidence-based recommendations from specialty organizations on commonly used ...

- PEDFIC 1meetsboth U.S. and EU primary and secondary endpoints with highlystatistically significant reductions in serum bile acids and pruritus- - Interim results from long-term extension studyshow ...

-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program -- At the meeting, one poster presentation ...

Vebicorvir Phase 2 open-label study data demonstrate the contribution of core inhibition to deepen viral suppression; Oral presentation scheduled for November 14 at 10 am ET “Through our core ...